A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma

You may be eligible if

• Eligibility Criteria:
• Adult patients with a physician-documented diagnosis of chronic, stable, persistent, mild to moderate asthma (clinical symptoms and documented reversibility of airway obstruction, with an FEV1 of 60% to 85% of the predicted value).
• The following criteria must be met at the randomisation visit:
• At least 80% compliance during the single-blind placebo run-in period
• FEV1 between 60% and 85% of the predicted value
• Without asthma exacerbation during the run-in period
• Reversibility: patients are required to demonstrate a ≥ 12% increase in FEV1 (with an absolute improvement in FEV1 of at least 200mL) ≥ 10 min and up to 15 minutes after inhalation of 400 μg salbutamol via a spacer
• Any symptom score being ≥ 1 for at least 4 out of the last 7 days of the run-in
• Use of salbutamol for symptom relief on \> 2 occasions on at least 4 out of the last 7 days of the run-in